Articles Archives

Articles Aug112025

Supreme-ly FRAND: Supreme Court grant Tesla permission to appeal in its FRAND pool rate-setting dispute with Avanci and InterDigital – but beware the limitations.

It’s been a busy few weeks for SEP/FRAND cases in the UK. The Supreme Court is now going to hear its first SEP/FRAND case since 𝑈𝑛𝑤𝑖𝑟𝑒𝑑 𝑃𝑙𝑎𝑛𝑒𝑡, granting Tesla permission to appeal in its dispute with Avanci and InterDigital concerning the UK court’s jurisdiction to make FRAND declarations in relation to a licensing pool (the Avanci 5G Platform).

Articles Aug052025

G1/25 – “Hydroponics”

Edward Rainsford discusses the Board of Appeal decision T697/22, a much-watched case that could have significant implications for future practice at the European Patent Office.

Articles Jul172025

Emotional Perception: Time to Face the Music?

Ahead of the next chapter in the ongoing UK proceedings regarding the ”Emotional Perception” patent application (application number GB1904713.3), our experts re-cap the story so far and share hopes on what might happen next.

Articles Jul012025

New UK IPO guidance on overly broad trade mark terms

Following the Supreme Court’s decision in SkyKick v Sky — on 27 June 2025, the UK IPO issued important guidance on how it will now approach trade mark applications — and it’s a significant shift. This article summarises what the new guidance means for trade mark applicants and businesses.

Articles Jul012025

UK SEP/FRAND interim licence declarations – an exercise of the Court’s jurisdiction or of ‘judicial imperialism’?

Last week, the High Court issued its judgment on interim FRAND licences in Samsung v ZTE.

Articles Jun262025

G1/24 Decision of the Enlarged Board of Appeal

The Enlarged Board of Appeal issued their decision in the case of G1/24 on 18 June 2025. Our experts discuss the relevance for IP professionals.

Articles Jun232025

When can legitimate goods be modified and resold using the original trade mark?

This article examines the legal principles of trade mark exhaustion and explores how brand owners can manage their reputation after goods have been sold.

Articles May292025

The power of organoids – advances in disease modelling research

In March 2025, the first Cambridge Human Organoid Symposium took place at Jesus College, Cambridge. Having attended, trainee patent attorney Oliver Herd shares the latest research findings presented.

Articles May222025

Targeting the undruggable proteome with molecular glues

Recent patent and clinical trial activity highlights a rising global interest in molecular glue research to improve patient outcomes for cancer, neurodegenerative, and autoimmune disease treatments.

Articles May132025

Patent filings in treatments for neurodegenerative disorders: a shift toward biotherapeutic innovation

This article explores a major shift in global patent filings for neurodegenerative disorder therapies over the past decade. Once dominated by big pharma’s small molecules, innovation is now increasingly led by SMEs developing biotherapeutics targeting root causes. This trend reflects rising interest in precision medicine and suggests progress toward more effective treatments beyond symptom management.

Articles May052025

Optus v Apple – CoA increases FRAND licence to $500m ($700m with interest) in favour of Optus

In a judgment that further swings the pendulum back towards the UK being a 'SEP-owner-friendly' jurisdiction, the CoA has set the terms of the FRAND licence payable by Apple at a little over $700m ($500m + $200m interest).